Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis.
暂无分享,去创建一个
F. J. Luque | Federico Gago | F Javier Luque | Sonsoles Martín-Santamaría | Jordi Muñoz-Muriedas | F. Gago | J. Muñoz-Muriedas | S. Martín-Santamaría | F. Luque
[1] F. J. Luque,et al. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. , 2000, Journal of medicinal chemistry.
[2] F. Gago,et al. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. , 2001, Journal of medicinal chemistry.
[3] F. J. Luque,et al. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. , 1999, Journal of medicinal chemistry.
[4] B. Honig,et al. A rapid finite difference algorithm, utilizing successive over‐relaxation to solve the Poisson–Boltzmann equation , 1991 .
[5] M Pastor,et al. Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethylketones. , 2001, Combinatorial chemistry & high throughput screening.
[6] Hugo Verli,et al. Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8]naphthyridine isosteres: a new class of potent and selective acetylcholinesterase inhibitors. , 2003, Journal of medicinal chemistry.
[7] A. Cavalli,et al. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. , 2000, Journal of medicinal chemistry.
[8] J L Sussman,et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. , 2002, Biochemistry.
[9] A. Castro,et al. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. , 2001, Mini reviews in medicinal chemistry.
[10] D Lamba,et al. Three‐dimensional structure of a complex of galanthamine (Nivalin®) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti‐Alzheimer drugs , 2001, Proteins.
[11] A. Ortiz,et al. Assessment of solvation effects on calculated binding affinity differences: trypsin inhibition by flavonoids as a model system for congeneric series. , 1997, Journal of medicinal chemistry.
[12] M. Emmerling,et al. Differentiation and distribution of acetylcholinesterase molecular forms in the mouse cochlea , 1988, Hearing Research.
[13] P. C. Hariharan,et al. The influence of polarization functions on molecular orbital hydrogenation energies , 1973 .
[14] R C Wade,et al. Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. , 2000, Journal of medicinal chemistry.
[15] R. Wade,et al. Prediction of drug binding affinities by comparative binding energy analysis , 1995 .
[16] L. Schneider,et al. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. , 2003, Current drug targets.
[17] A. Cavalli,et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. , 2003, Journal of medicinal chemistry.
[18] P. Taylor,et al. Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants. , 1992, Biochemistry.
[19] K. Sharp,et al. Calculating the electrostatic potential of molecules in solution: Method and error assessment , 1988 .
[20] Luhua Lai,et al. Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..
[21] J. Briggs,et al. ON THE MECHANISM OF ACETYLCHOLINESTERASE ACTION : THE ELECTROSTATICALLY INDUCED ACCELERATION OF THE CATALYTIC ACYLATION STEP , 1997 .
[22] C. Lipinski,et al. Physical parameters for brian uptake: optimizing log P, log D and pKa of T H A , 1991 .
[23] Marta Murcia,et al. Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. , 2004, Journal of medicinal chemistry.
[24] F. J. Luque,et al. Rational design of reversible acetylcholinesterase inhibitors. , 2002, Mini reviews in medicinal chemistry.
[25] Jirí Damborský,et al. Comparative binding energy analysis of haloalkane dehalogenase substrates: Modelling of enzyme-substrate complexes by molecular docking and quantum mechanical calculations , 2003, J. Comput. Aided Mol. Des..
[26] N. Inestrosa,et al. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. , 1997, Journal of molecular biology.
[27] Federico Gago,et al. Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles. , 2004, Journal of the American Chemical Society.
[28] P. Kollman,et al. A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .
[29] B. A. Luty,et al. Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach , 2000 .
[30] Zoran Radić,et al. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site , 2003, The EMBO journal.
[31] C. J. Moore,et al. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties , 1992 .
[32] J. Sussman,et al. Reaction Products of Acetylcholinesterase and VX Reveal a Mobile Histidine in the Catalytic Triad , 1999 .
[33] Ferran Sanz,et al. 3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..
[34] N. Ariel,et al. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. , 2000, Acta crystallographica. Section D, Biological crystallography.
[35] J. Sussman,et al. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.
[36] Yuan-Ping Pang,et al. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. , 2003, Journal of the American Chemical Society.
[37] W. Foye,et al. Principles of medicinal chemistry , 1974 .
[38] Wolfgang Sippl,et al. Design, Synthesis, and Structure—Activity Relationships of a Series of 3‐[2‐(1‐Benzylpiperidin‐4‐yl)ethylamino]pyridazine Derivatives as Acetylcholinesterase Inhibitors. , 2001 .
[39] Johan Åqvist,et al. Ligand binding affinity prediction by linear interaction energy methods , 1998, J. Comput. Aided Mol. Des..
[40] Ajay,et al. Computational methods to predict binding free energy in ligand-receptor complexes. , 1995, Journal of medicinal chemistry.
[41] Peter A. Kollman,et al. FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .
[42] M Pastor,et al. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. , 1998, Journal of medicinal chemistry.
[43] A Caflisch,et al. Computational ligand design. , 1999, Combinatorial chemistry & high throughput screening.
[44] K. Courtney,et al. A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.
[45] J. Sussman,et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[46] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[47] R. Wade,et al. Prediction of drug binding affinities by comparative binding energy analysis. , 1997, Journal of medicinal chemistry.
[48] F. J. Luque,et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. , 2002, Biochemistry.
[49] G. Klebe,et al. Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.
[50] R. Wade,et al. Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. , 2001, Journal of medicinal chemistry.
[51] F. J. Luque,et al. Predicting relative binding free energies of tacrine-huperzine A hybrids as inhibitors of acetylcholinesterase. , 1999, Journal of medicinal chemistry.
[52] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[53] R C Wade,et al. Comparative binding energy analysis of the substrate specificity of haloalkane dehalogenase from Xanthobacter autotrophicus GJ10. , 2001, Biochemistry.
[54] A. Goldman,et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.